
Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Filed with SSE · · 3 pages · Chinese and English
The application is based on a phase three clinical trial that demonstrated significant survival benefits for patients with high-volume metastatic hormone-sensitive prostate cancer. The company emphasizes the need for cautious investment decisions due to the uncertainties involved in the drug approval process.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals